IMI 2023 Digest
Investigative Opthalmology & Visual Science · 2023-05-01 · 64 (6) · 7
DOI: 10.1167/iovs.64.6.7 ↗At a glance
Journal article in Investigative Opthalmology & Visual Science, published online on 2023-05-01. Written by Padmaja Sankaridurg and 12 co-authors. Institution: Brien Holden Vision Institute, Sydney, Australia. Major MEDLINE topics: Myopia, Contact Lenses, Hydrophilic. Cited 121 times so far (Crossref); 241 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Myopia is a dynamic and rapidly moving field, with ongoing research providing a better understanding of the etiology leading to novel myopia control strategies. In 2019, the International Myopia Institute (IMI) assembled and published a series of white papers across relevant topics and updated the evidence with a digest in 2021. Here, we summarize findings across key topics from the previous 2 years. Studies in animal models have continued to explore how wavelength and intensity of light influence eye growth and have examined new pharmacologic agents and scleral cross-linking as potential strategies for slowing myopia. In children, the term premyopia is gaining interest with increased attention to early implementation of myopia control. Most studies use the IMI definitions of ≤-0.5 diopters (D) for myopia and ≤-6.0 D for high myopia, although categorization and definitions for structural consequences of high myopia remain an issue. Clinical trials have demonstrated that newer spectacle lens designs incorporating multiple segments, lenslets, or diffusion optics exhibit good efficacy. Clinical considerations and factors influencing efficacy for soft multifocal contact lenses and orthokeratology are discussed. Topical atropine remains the only widely accessible pharmacologic treatment. Rebound observed with higher concentration of atropine is not evident with lower concentrations or optical interventions. Overall, myopia control treatments show little adverse effect on visual function and appear generally safe, with longer wear times and combination therapies maximizing outcomes. An emerging category of light-based therapies for children requires comprehensive safety data to enable risk versus benefit analysis. Given the success of myopia control strategies, the ethics of including a control arm in clinical trials is heavily debated. IMI recommendations for clinical trial protocols are discussed.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Brien Holden Vision Institute, Sydney, Australia.
- School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.
- University of Houston, College of Optometry, Houston, Texas, United States.
- West China Hospital, Sichuan University, Sichuan, China.
- Eye & ENT Hospital of Fudan University, Shanghai, China.
- Affiliated Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Cite
APA
Sankaridurg, P., Berntsen, D. A., Bullimore, M. A., Cho, P., Flitcroft, I., Gawne, T. J., Gifford, K. L., Jong, M., Kang, P., Ostrin, L. A., Santodomingo-Rubido, J., Wildsoet, C., & Wolffsohn, J. S. (2023). IMI 2023 Digest. Investigative Opthalmology & Visual Science, 64(6), 7. https://doi.org/10.1167/iovs.64.6.7
Vancouver
Sankaridurg P, Berntsen DA, Bullimore MA, Cho P, Flitcroft I, Gawne TJ, et al. IMI 2023 Digest. Investigative Opthalmology & Visual Science. 2023;64(6):7. doi:10.1167/iovs.64.6.7
BibTeX
@article{Sankaridurg2023,
author = {Sankaridurg, Padmaja and Berntsen, David A and Bullimore, Mark A and Cho, Pauline and Flitcroft, Ian and Gawne, Timothy J and Gifford, Kate L and Jong, Monica and Kang, Pauline and Ostrin, Lisa A and Santodomingo-Rubido, Jacinto and Wildsoet, Christine and Wolffsohn, James S},
title = {IMI 2023 Digest},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
volume = {64},
number = {6},
pages = {7},
doi = {10.1167/iovs.64.6.7}
}
EUVIMED